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Abstract
Background: Serum leptin level is associated with appetite and energy expenditure in healthy
individuals. We aimed to evaluate the serum leptin concentration and the other factors which may
be associated with weight loss in patients with advanced gastrointestinal cancer.
Methods: Forty-four patients with advanced gastrointestinal cancer (25 gastric and 19 colorectal
cancer) and 25 healthy controls were enrolled. Serum leptin levels were measured as ng/ml via
enzyme linked immuno-sorbent assay (ELISA) method in all subjects. The difference in serum leptin
concentration between cancer and control group, the factor associated with its serum level and
the relationship between serum leptin concentration and weight loss was evaluated.
Results: Serum leptin concentration of cancer group was significantly lower than controls (p =
0.002). Female subjects had significantly higher serum leptin concentration than male subjects in
control group (p = 0.01), while not in cancer group (p > 0.05). Serum leptin concentration was
significantly related with gender in controls (p = 0.023, β = 0.479), while no gender difference was
observed in cancer group (p > 0.05). No relationship was found between serum leptin
concentration and weight loss percentage in cancer group in linear regression analysis (p > 0.05).
No significant difference was observed in serum leptin concentrations between colon and gastric
cancer sub-groups (p > 0.05).
Conclusion: Independently from the site of gastrointestinal tract, serum leptin concentration in
advanced gastrointestinal cancer is lower than controls and it is not a determinant factor in weight
loss. In contrast to healthy subjects, gender does not effect the serum leptin concentration in
patients with advanced gastrointestinal cancer.
Background
Leptin, a 16-kilodalton protein, is involved in the regula-
tion of food intake and body composition, as discovered
by Friedman et al [1,2]. It is a member of the cytokine
family, most closely related to ciliary neutrotropic factor
and to leukemia inhibitory factor [2]. Plasma leptin level
Published: 24 June 2004
BMC Cancer 2004, 4:29 doi:10.1186/1471-2407-4-29
Received: 16 March 2004
Accepted: 24 June 2004
This article is available from: http://www.biomedcentral.com/1471-2407/4/29
© 2004 Bolukbas et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all 
media for any purpose, provided this notice is preserved along with the article's original URL. BMC Cancer 2004, 4 http://www.biomedcentral.com/1471-2407/4/29
Page 2 of 4
(page number not for citation purposes)
is correlated with body fat percentages, suggesting that
leptin is an important signal of fat stores [3,4]. In healthy
individuals, decrease in leptin increases neuropeptide Y
production in the hypothalamus, which in turn increases
appetite and decreases energy expenditure. As a result, fat
storage increases [5].
Weight loss in cancer patients remains a major clinical
problem because it contributes to loss of independence
and compromises the quality of life [6,7]. There is increas-
ing evidence in the literature that the inflammatory
response plays an important role in such alterations in
gastrointestinal cancer patients [8,9]. Several inflamma-
tory cytokines, especially tumour necrosis factor (TNF),
interleukin 1(IL-1), interleukin 6 (IL-6), and ciliary neu-
trotropic factor (CNTF), induce anorexia and cachexia
[10,11]. The serum leptin level and its role in the weight
loss of patients with advanced cancer are still controver-
sial. In one study which was conducted in patients with
colorectal cancer, serum leptin level has been found to be
similar with controls [12]. In contrast, in other studies,
low or undetectable circulating leptin concentrations have
been observed in patients with lung and gastrointestinal
cancer [13,14]. The net effect of these various observations
on cancer patients is largely unknown.
The aim of the present study was to evaluate the serum
leptin concentration in patients with advanced gastroin-
testinal cancer and to determine the factors such as gen-
der, age and body mass index (BMI) which may be related
with this peptide in this subjects. In addition, we aimed to
find out the relationship of leptin with weight loss and to
compare the serum leptin concentrations in distinct type
of gastrointestinal cancers.
Methods
Forty-four cancer patients with histologically confirmed
stage IV gastrointestinal malignancy with more than 5%
weight loss in previous six months who had life expect-
ancy of at least two months (25 gastric and 19 colorectal
cancers) and 25 healthy controls were enrolled in this
study. Patient group was composed from outpatients of
Oncology Department. Control group was selected from
completely healthy subjects with stable weight. Patients
with diabetes mellitus, hypertension, renal and hepatic
insufficiency, and major depression, active problem to
interfere with oral intake and who were under active
chemotherapy were excluded from the study. The study
was approved by the local human institutional review
committee and written consents were received from all
participants.
Body weight of subjects with wearing standard clothes
and no shoes in two groups was determined using a cali-
brated beam scale. A Harpender Statiometer was used in
height measurement. Body mass index (BMI) was deter-
mined as the actual body weight divided by the square of
height (kg/m2). Body weight and BMI which were
assessed six months earlier and obtained from the outpa-
tient data records were accepted as baseline values. After
obtaining baseline and actual values, the percentage of
lost in body weight and BMI was calculated.
Blood samples were obtained in the morning after 12
hours of fasting period following anthropometric meas-
urements. Routine blood tests were performed in all sub-
jects using auto-analyser. Serum leptin levels were
measured as ng/ml via enzyme linked immuno-sorbent
assay (ELISA) method by using Kat./cat: DX-EIA-1863,
Test:96 Wells 11/0 (DRG International Inc., New Jersey,
USA) in all subject. Reported leptin concentrations were
the mean of two determinations of the same sample. Sen-
sitivity of the test was 0.10 ng/ml.
Statistical analysis
Data were reported as median and range. Continuous var-
iables were compared using Mann-Whitney U or Kruskal-
Wallis H test. A linear regression analysis was used to
determine the variables related with the serum leptin lev-
els. The statistical significance was defined as a p < 0.05.
Statistical analyses were performed using the SPSS 9.0 for
windows.
Results
Clinical and demographic characteristics of malignant
and control group were shown in table 1. Median BMI val-
ues were significantly higher in control group (p = 0.008),
while median age in cancer group (p < 0.001). No statisti-
cally significant differences were observed in male and
female number of the groups (P > 0.05). In each group,
male and female subjects had similar age and BMI (both,
p > 0.05). Median weight loss was 9.1% and 8.8% in
female and male subjects of cancer group, respectively (p
> 0.05). (Table 2)
Serum leptin concentration of cancer group was signifi-
cantly lower than controls (p = 0.002). Female subjects
had significantly higher serum leptin concentration than
male subjects in control group (p = 0.01), while not in
cancer group (p > 0.05). (Table 2)
Linear regression analysis showed that serum leptin con-
centration was significantly related with gender in con-
trols (p = 0.023, β = 0.479), while no gender difference
was observed in cancer group (p > 0.05). Serum leptin
concentration was not related to age and BMI in both
groups (both, p > 0.05). No relationship was found
between serum leptin concentration and weight loss per-
centage in cancer group in linear regression analysis (p >
0.05).BMC Cancer 2004, 4 http://www.biomedcentral.com/1471-2407/4/29
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When the cancer group was sub-grouped according to
type of cancer (e.g. colon and gastric), control subjects
had significantly higher serum leptin concentration than
two cancer sub-groups (both, p < 0.016). No significant
difference was observed in serum leptin concentrations
between colon and gastric cancer sub-group (p > 0.05).
(Table 1)
Discussion
Primary aim of the present study was to evaluate the
serum leptin concentration in advanced gastrointestinal
cancer patients. We have found a significant decrease in
serum leptin concentrations of cancer group compared to
controls. Although it is still controversial, serum leptin
concentration has been reported to be lower than con-
trols, especially in the lung and colorectal cancer, in the
literature. It has been suggested that low serum leptin con-
centration may be related to decreased body fat mass in
this subjects [13,14]. Tessitore et al [12] reported that
patients with breast cancer had higher serum leptin con-
centration than controls. However, they did not observed
any increase in serum leptin concentration in patients
with colorectal cancer compared to controls. No mecha-
nism related to these results has been suggested by this
author [12]. Median weight loss has reached up to 8% in
our cancer patients. Therefore decrease in leptin concen-
tration may be related to decreased body fat mass which
was developed secondary to weight loss in our patients.
It has been reported that healthy women have more adi-
pose tissue and consequently have higher leptin concen-
trations than men with equivalent BMI [14,15]. Similarly,
in the present study, serum leptin concentrations were
higher in women than in men in controls, while not in
cancer group. Linear regression analysis has shown that
serum leptin concentration was only related with gender
in controls, however, there was no relationship between
gender and serum leptin concentration in cancer group.
This observation may indicate that gender factor is not a
determinant for serum leptin level in patients with
advanced gastrointestinal cancer. As reported previously
[14,16], other parameters such as BMI and age were not
related with serum leptin concentration neither in con-
trols nor in cancer patients. Inflammatory cytokines have
been suggested to influence serum leptin concentrations
[17], whereas conflicting results have been reported in the
literature [18]. The influence of these cytokines on serum
leptin concentrations couldn't be investigated in the
present study.
In our study, body weight loss percentage was not related
with leptin concentration in cancer group in linear
regression analysis. This finding was consistent with the
literature [13,14,19]. In the healthy subjects a decrease in
serum leptin concentration appears to stimulate an
increase in neuropeptide Y from the hypothalamus and
this, in turn, results in increased appetite and decreased
Table 1: Characteristics of control and study groups.
Gastric cancer group Colorectal cancer 
group
Malignant group Control group
n 2 51 94 42 5
Sex m/f 16/9 13/6 29/15 12/13
Age (year) 58 (34–80) 59 (33–80) 58 (33–80)* 38 (22–67)*
Body mass index (kg/m2) 22 (17–24) 23 (16–25) 22 (16–25)** 25 (21–28)**
Weight loss percentage (%) 7.8 (5.3–23.8) 8.4 (5.2–19) 8.1 (5.2–23.8) ------
Leptin (ng/ml) 1.8 (0.1–12) 1.9 (0.2–11) 1.8 (0.1–12)*** 3 (2.5–13)***
Data were reported as median and range. *p < 0.001 **p = 0.008 ***p = 0.002
Table 2: Comparison of cancer and control groups based on gender
Cancer group (n = 44) Control group (n = 25)
female (n = 15) male (n = 29) female (n = 13) male (n = 12)
Leptin (ng/ml) 1.8 (0.2–12) 1.8 (0.1–10) 5.7 (2.3–13)* 2.5 (2–11.2)*
Body mass index (kg/
m2)
22 (19–24) 21 (16–25) 24 (21–28) 25 (22–28)
Weight loss (kg) 9.1 (5.2–21) 8.8 (5.6–23.8) ---- ----
Data were reported as median and range. *p = 0.01BMC Cancer 2004, 4 http://www.biomedcentral.com/1471-2407/4/29
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energy utilization [5]. Although decrease in serum leptin
concentration in cancer patients has been reported in pre-
vious studies, no increase in appetite and decrease in
energy expenditure have been observed in these subjects.
This finding has been suggested to be due to a block in the
hypothalamic response to low circulating leptin concen-
trations in such cancer patients [13,14,20]. In the present
study, the lack of relationship between serum leptin con-
centration and body weight loss percentage, and decrease
in serum leptin concentration suggested that leptin level is
not a causative factor in weight loss in patients with gas-
trointestinal cancer.
In addition to findings mentioned above, we have also
found no difference between patients with advanced gas-
tric and colorectal cancer in regarding to serum leptin con-
centrations. This finding has not been reported in
previous studies. This suggested that serum leptin concen-
tration is not affected from the site of advanced stage can-
cer of gastrointestinal tract and it is constantly low in these
subjects.
Conclusion
Independently from the involved site of the gastrointesti-
nal tract, serum leptin concentration in advanced gas-
trointestinal cancer is lower than controls and it is not a
determinant factor in weight loss. In contrast to healthy
subjects, gender does not effect the serum leptin concen-
tration in patients with advanced gastrointestinal cancer.
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